Cargando…

Rituximab for the treatment of patients with chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder that originates from antigen-experienced B lymphocytes that do not die and hence accumulate due to external survival signals or undergo apoptosis and are replenished by proliferating precursors. These neoplastic lymphocytes exhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gentile, M, Vigna, E, Mazzone, C, Lucia, E, Recchia, AG, Morabito, L, Bisconte, MG, Gentile, C, Morabito, F
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004569/ https://www.ncbi.nlm.nih.gov/pubmed/21188098

Ejemplares similares

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
por: Morabito, Fortunato, et al.
Publicado: (2021)

Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia
por: Ronchetti, Domenica, et al.
Publicado: (2013)

lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome
por: Ronchetti, D, et al.
Publicado: (2016)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
por: Bryan, Jeffrey, et al.
Publicado: (2011)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
por: Botta, Cirino, et al.
Publicado: (2020)

RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
por: Castro, Januario E., et al.
Publicado: (2009)

Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia
por: Maura, Francesco, et al.
Publicado: (2011)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques
por: Recchia, Anna Grazia, et al.
Publicado: (2015)

LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells
por: Matis, Serena, et al.
Publicado: (2021)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)
por: Al-Kali, Aref, et al.
Publicado: (2010)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2015)

Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression
por: Barisione, G, et al.
Publicado: (2017)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?
por: Molica, Stefano, et al.
Publicado: (2009)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Woyach, Jennifer A, et al.
Publicado: (2009)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome
por: Ronchetti, Domenica, et al.
Publicado: (2020)

Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
por: Morabito, Fortunato, et al.
Publicado: (2023)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience
por: Shadman, Mazyar, et al.
Publicado: (2019)

Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
por: Monti, Paola, et al.
Publicado: (2020)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
por: Shustik, C., et al.
Publicado: (2017)

MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
por: Matis, Serena, et al.
Publicado: (2022)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China
por: XU, ZHENSHU, et al.
Publicado: (2013)

Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases
por: Eren, Rafet, et al.
Publicado: (2018)

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Fraser, G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s8i4lbrufscthdj089f1198oid